Tetra is committed to building a leading portfolio of clinical trial stage treatments, based on phosphodiesterase sub-type inhibitors for both neuroscience and non-neuroscience disorders. These are fields in which we believe Tetra is poised to deliver multiple novel treatments, with the potential to change patients’ lives.
Tetra is actively seeking potential commercial partners for our two drug programs, PDE4D and PDE4B inhibitors, as well as Fragile X Syndrome; Alzheimer’s disease; schizophrenia/cognition; and traumatic brain injury drug projects. In partnerships, we seek to effectively leverage Tetra’s drug discovery platform and know-how with the clinical translation expertise of the pharma partner. We are also interested in novel therapeutic opportunities linking phosphodiesterases to other peripheral as well as central diseases.
Tetra Discovery Partners, Inc. is a leader in the chemical design of inhibitors of phosphodiesterase (PDE) enzymes. Tetra’s lead compound, BPN14770, is designed to treat behavior and cognition in Fragile X Syndrome patients and memory loss in early-to-moderate Alzheimer’s disease patients. Memory loss is also a major consequence of traumatic brain injury. The cAMP/protein kinase A/pCREB signaling pathway is down-regulated after traumatic brain injury.
Tetra’s drug discovery platform uses a chemistry structure-guided drug design approach to discover mechanistically novel inhibitors of phosphodiesterase 4 (PDE4) subtypes such as PDE4B and PDE4D. Tetra is able to design drug inhibitors that have greater tolerability than earlier compounds, while enhancing efficacy.
In the brain, PDEs are involved in cognition/memory, schizophrenia, depression and neuroinflammation. Tetra’s focus is to address the functioning of PDE4s to enhance memory formation in brain neurons, nerve dendrites involved in schizophrenia and depression, and brain microglia involved in brain inflammation. Tetra’s drug discovery platform can also be used to develop novel treatments for peripheral diseases where PDEs are attractive drug targets.
If you are interested in partnering with Tetra, please contact Mr. Joseph Collard, Chief Business Officer, at email@example.com.
The progress of Tetra’s 3 leading programs